NVCT - NASDAQ
Nuvectis Pharma, Inc.
$9.42
-0.95%Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
At a Glance
Live SnapshotNuvectis Pharma, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Nuvectis Pharma, Inc. Balance Sheet
NVCT • NASDAQ
| Nuvectis Pharma, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
ASSETS | ||||||
CURRENT ASSETS | ||||||
31.6M | 18.5M | 19.1M | 20M | 5.7M | 0.0 | |
31.6M | 18.5M | 19.1M | 20M | 5.7M | 0.0 | |
75K | 74K | 59K | 412K | 91K | 0.0 | |
31.7M | 18.6M | 19.2M | 20.4M | 5.8M | 0.0 | |
NON-CURRENT ASSETS | ||||||
0.0 | 0.0 | 0.0 | 0.0 | 824K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 824K | 0.0 | |
31.7M | 18.6M | 19.2M | 20.4M | 6.7M | 0.0 | |
LIABILITIES | ||||||
CURRENT LIABILITIES | ||||||
6.3M | 2.5M | 2.8M | 3.4M | 1.9M | 10K | |
6.3M | 2.5M | 2.8M | 2.9M | 1.1M | 10K | |
0.0 | 0.0 | 0.0 | 450K | 824K | 0.0 | |
0.0 | 840K | 415K | 445K | 395K | 0.0 | |
7M | 5.6M | 3.8M | 2.4M | 142K | 0.0 | |
13.3M | 8.9M | 7M | 6.2M | 2.4M | 10K | |
NON-CURRENT LIABILITIES | ||||||
0.0 | 0.0 | 0.0 | 0.0 | 15.2M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 15.2M | 0.0 | |
13.3M | 8.9M | 7M | 6.2M | 17.7M | 10K | |
SHAREHOLDERS' EQUITY | ||||||
0.0 | 83M | 66.4M | 46.2M | 1.9M | 0.0 | |
-99.7M | -73.2M | -54.2M | -32M | -12.9M | -10K | |
118.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
18.4M | 9.7M | 12.2M | 14.2M | -11M | -10K | |
18.4M | 9.7M | 12.2M | 14.2M | -11M | -10K | |
SUMMARY | ||||||
31.7M | 18.6M | 19.2M | 20.4M | 6.7M | 0.0 | |
-31.6M | -18.5M | -19.1M | -20M | -5.7M | 0.0 | |
25,456,848 | 25,456,848 | 25,456,848 | 25,456,848 | 25,456,848 | 25,456,848 |
SEC Filings
NVCT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 11, 2026 | 2026 | |
S-3 S-3 N/A | February 13, 2026 | February 13, 2026 | ||
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 11, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 25, 2025 | September 22, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 05, 2025 | August 05, 2025 | 2025 |
Related Guides
Continue your NVCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.